Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Cyclophosphamide
  • Ovarian Neoplasms
  • Paclitaxel

abstract

  • Incorporating paclitaxel into first-line therapy improves the duration of progression-free survival and of overall survival in women with incompletely resected stage III and stage IV ovarian cancer.

publication date

  • January 4, 1996

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJM199601043340101

PubMed ID

  • 7494563

Additional Document Info

start page

  • 1

end page

  • 6

volume

  • 334

number

  • 1